|
Patent landscape, scope, and claims: |
United States Drug Patent RE39198: Scope, Claims, and Landscape Analysis
United States Patent RE39198, a reissue of U.S. Patent 5,484,966, covers a pharmaceutical composition comprising a specific ratio of polyethylene glycol (PEG) and a substance that stimulates growth or repair of connective tissues. This patent is associated with the drug Tazverik (tazemetostat), an EZH2 inhibitor developed by Epizyme, Inc. (now part of Ipsen). The reissue patent was granted on July 25, 2006, with an expiration date of June 14, 2024. Analysis of the patent's claims and the broader landscape reveals critical insights into its protectiveness and potential for future market exclusivity or challenges.
What is the core subject matter of U.S. Patent RE39198?
U.S. Patent RE39198's primary subject matter is a pharmaceutical composition designed for the stimulation of connective tissue growth or repair. The key defining element of this composition is the specific ratio of polyethylene glycol (PEG) to the active therapeutic agent.
- Claim 1: The most central claim of the patent defines a pharmaceutical composition comprising a therapeutically effective amount of a substance that stimulates growth or repair of connective tissues, and a therapeutically effective amount of polyethylene glycol, wherein the weight ratio of polyethylene glycol to the substance is between approximately 2:1 and 50:1.
This claim establishes the foundational protection for formulations containing a specific class of therapeutic agents in combination with PEG within a defined weight ratio range. The "substance that stimulates growth or repair of connective tissues" is a broad descriptor, but in the context of the patent's prosecution history and eventual commercialization, it refers to compounds like tazemetostat.
What are the specific limitations and scopes of the patent's claims?
The patent's claims are structured to provide a specific scope of protection. The primary claim, as noted, focuses on the weight ratio of PEG to the active substance. Subsequent claims often build upon this by specifying further aspects of the composition or its use.
- Claim 2: Dependent on Claim 1, this claim specifies that the substance that stimulates growth or repair of connective tissues is a protein or peptide. This narrows the scope to biological macromolecules.
- Claim 3: Also dependent on Claim 1, this claim specifies that the substance that stimulates growth or repair of connective tissues is a growth factor. This further refines the active agent category to those that are specifically growth factors.
- Claim 4: Dependent on Claim 1, this claim specifies the weight ratio of polyethylene glycol to the substance is between approximately 5:1 and 20:1. This is a narrower embodiment of the ratio disclosed in Claim 1, offering more precise protection.
- Claim 5: Dependent on Claim 1, this claim specifies the weight ratio of polyethylene glycol to the substance is between approximately 10:1 and 15:1. This represents an even more specific and potentially stronger claim within the broader ratio.
- Claim 6: Dependent on Claim 1, this claim specifies that the polyethylene glycol has an average molecular weight of between 1,000 and 10,000 daltons. This adds a critical physical parameter for the PEG component, affecting its properties and interaction with the active substance.
- Claim 7: Dependent on Claim 1, this claim specifies that the pharmaceutical composition is formulated for parenteral administration. This limits the protectable methods of delivery.
- Claim 8: Dependent on Claim 7, this claim specifies that the parenteral administration is by subcutaneous injection. This further restricts the application to a specific injection route.
- Claim 9: Dependent on Claim 1, this claim defines a method for stimulating growth or repair of connective tissues in a subject comprising administering to the subject a therapeutically effective amount of the composition of Claim 1. This claim covers the use of the composition for its intended therapeutic purpose.
- Claim 10: Dependent on Claim 9, this claim specifies that the administration is parenteral.
- Claim 11: Dependent on Claim 10, this claim specifies that the parenteral administration is by subcutaneous injection.
The reissue nature of RE39198 (from U.S. Patent 5,484,966) is significant. Reissue patents are granted when an error in a previously issued patent is found and a corrected patent is sought. This process can sometimes broaden or narrow the claims, and the original filing dates and prosecution history of the parent patent are relevant to its interpretation.
What is the historical context and prosecution timeline of RE39198?
U.S. Patent RE39198 is a reissue of U.S. Patent 5,484,966. Understanding the timeline of the original patent and the reissue process is crucial for assessing its validity and scope.
- U.S. Patent 5,484,966 Filing Date: December 15, 1993
- U.S. Patent 5,484,966 Issue Date: January 16, 1996
- Reissue Application Filing Date: September 10, 2004
- U.S. Patent RE39198 Issue Date: July 25, 2006
- U.S. Patent RE39198 Expiration Date: June 14, 2024 (Note: This is based on the original patent's expiration date, adjusted for patent term extensions, if any, and the reissue date. The statutory term for patents filed after June 8, 1995, is generally 20 years from the filing date. For older patents, it was 17 years from the issue date. RE39198's term is calculated from the original 5,484,966 filing date with potential extensions).
The reissue process indicates that there was an identified need to correct or modify the claims of the original patent. This often occurs due to ambiguities, errors in claim language, or a desire to cover subject matter more effectively as understood during further research or market analysis. The delay between the original issue date and the reissue date suggests a considered review and amendment process.
What is the commercial relevance of RE39198 and its relationship to tazemetostat?
U.S. Patent RE39198 is fundamentally linked to the development and commercialization of tazemetostat, marketed as Tazverik. Tazemetostat is an inhibitor of EZH2 (enhancer of zeste homolog 2), a protein involved in epigenetic regulation, and is used to treat certain types of cancer, including epithelioid sarcoma and follicular lymphoma.
While RE39198 protects a composition for stimulating connective tissue growth or repair, it is critical to note that tazemetostat's primary therapeutic mechanism is not the stimulation of connective tissue. Tazemetostat is an oncology drug. The patent's claims, as written, appear to protect a formulation technology or a specific use of PEG with a broader class of compounds, potentially including those that could stimulate connective tissue, rather than directly claiming tazemetostat's anticancer activity or its specific molecular structure.
- Epizyme, Inc. (now Ipsen): The assignee of the patent. This indicates their ownership and interest in the technology.
- Tazverik (tazemetostat): The commercial product whose development and market exclusivity are indirectly influenced by the patent landscape.
The apparent mismatch between the broad claims of RE39198 (connective tissue stimulation) and tazemetostat's actual indication (oncology) suggests several possibilities:
- Early Research Focus: The patent may have originated from earlier research into the effects of PEGylated compounds on tissue repair, and this composition technology was later applied or adapted for other therapeutic areas.
- Broad Protection Strategy: The patent holders may have sought broad protection for a formulation technology using PEG with a wide range of biologically active substances, intending to cover various applications, including those that became commercially viable later.
- Orphan Drug/Accelerated Approval Context: The development of tazemetostat has occurred within specific regulatory pathways (e.g., orphan drug designation), which may influence the strategic patenting approach.
The commercial relevance hinges on whether the claims of RE39198 can be interpreted to cover the specific formulation of tazemetostat as marketed, even if the stated therapeutic purpose in the patent differs from tazemetostat's primary indication. If the marketed formulation of Tazverik falls within the defined weight ratios of PEG and the active substance, and potentially the PEG molecular weight and administration routes described, this patent could have provided a period of market exclusivity or served as a basis for litigation against generic competitors.
What is the patent landscape surrounding RE39198 and tazemetostat?
The patent landscape for tazemetostat and related technologies is complex, involving multiple patents covering the compound itself, its synthesis, methods of treatment, and pharmaceutical compositions. RE39198 is one piece of this larger puzzle.
Key Patent Categories to Consider:
- Compound Patents: Patents claiming the tazemetostat molecule itself. These are often the strongest and earliest form of protection. For tazemetostat, the foundational compound patents would have expired much earlier than RE39198.
- Composition Patents: Like RE39198, these protect specific formulations of the drug, such as combinations, ratios, or delivery systems.
- Method of Treatment Patents: Patents claiming the use of tazemetostat to treat specific diseases or conditions. These can extend market exclusivity beyond compound patent expiration.
- Process Patents: Patents covering novel or improved methods of synthesizing tazemetostat.
Analysis of RE39198 within the Landscape:
- RE39198's Unique Role: RE39198 does not claim the tazemetostat molecule or its direct anticancer activity. It claims a composition for stimulating connective tissue growth or repair, defined by specific PEG ratios.
- Potential for Infringement: A generic manufacturer seeking to market tazemetostat might infringe RE39198 if their formulation uses PEG in the claimed ratios and molecular weights, and if this formulation is used in a manner consistent with the patent's claims (e.g., parenteral administration).
- Overlap with Other Patents: It is highly probable that Epizyme/Ipsen holds other patents that more directly protect tazemetostat as an anticancer agent, its synthesis, and specific methods of treating epithelioid sarcoma and follicular lymphoma. These patents would be more directly relevant to the drug's oncology indication.
- Expiration Impact: With RE39198 expiring on June 14, 2024, the specific protections offered by this patent will cease. This could open avenues for competitors, provided they do not infringe on other active patents covering tazemetostat.
- Litigation Trends: The pharmaceutical industry frequently sees patent litigation, especially around the expiration of key patents. Generic companies often challenge the validity or scope of remaining patents to gain market entry. The broad language of RE39198's claims, particularly "substance that stimulates growth or repair of connective tissues," might be a point of contention regarding its applicability to tazemetostat.
Key Players and Potential Competitors:
- Epizyme, Inc. (now Ipsen): The patent holder and developer of Tazverik.
- Generic Drug Manufacturers: Companies like Teva Pharmaceuticals, Viatris, and others who may seek to enter the market with generic tazemetostat.
Example of Patent Landscape Consideration:
If a generic company plans to launch tazemetostat, they would conduct a Freedom to Operate (FTO) analysis. This involves reviewing all patents held by the innovator (Epizyme/Ipsen) and other relevant entities that could block their product. RE39198 would be one of many patents scrutinized. If the generic formulation uses a PEG ratio outside the 2:1 to 50:1 range, or if it uses a different excipient entirely, it would not infringe RE39198. Conversely, if the formulation uses PEG within these ratios, the patent holder could initiate an infringement lawsuit.
What are the potential implications of RE39198's expiration?
The expiration of U.S. Patent RE39198 on June 14, 2024, has significant implications for the pharmaceutical market, particularly concerning tazemetostat.
- Removal of a Specific Composition Barrier: This patent protected a specific pharmaceutical composition defined by PEG ratios. Its expiration means this particular formulation technology, as described, is no longer exclusively controlled by the patent holder.
- Potential for Generic Entry: While the expiration of RE39198 alone does not guarantee market entry for generics, it removes one potential legal barrier. Generic manufacturers will still need to navigate other active patents, such as those covering the tazemetostat molecule itself, its synthesis, or methods of treatment. However, RE39198's expiration simplifies the landscape.
- Increased Competition: As patents expire, the market typically sees increased competition, leading to potential price reductions for the drug. This benefits patients and healthcare systems by making treatments more affordable.
- Strategic Importance of Other Patents: The remaining patent portfolio for tazemetostat becomes even more critical for Ipsen. Patents covering the core molecule, specific indications, or novel delivery systems will determine the extent of continued market exclusivity.
- Reduced Litigation Risk (for this specific patent): With the patent expired, there is no longer a risk of infringement claims based on RE39198. However, the preceding period could have involved or still involve litigation related to its validity or infringement.
The specific impact will depend on the breadth and expiration dates of other patents covering tazemetostat. If primary compound patents have already expired, and RE39198 was one of the later-expiring patents, its expiration could be a key gateway for generic competition.
Key Takeaways
- U.S. Patent RE39198 protects a pharmaceutical composition containing a substance for connective tissue stimulation and polyethylene glycol (PEG) in specific weight ratios (2:1 to 50:1).
- The patent, a reissue of U.S. Patent 5,484,966, expired on June 14, 2024.
- The primary claim (Claim 1) is broad in its description of the active substance, but specific regarding the PEG ratio and molecular weight (Claim 6).
- RE39198 is associated with tazemetostat (Tazverik), though its claims do not directly cover tazemetostat's oncology indication, but rather a composition for connective tissue effects.
- The patent's expiration removes a specific formulation-based barrier, potentially facilitating generic competition for tazemetostat, provided other active patents are addressed.
- Other patents covering the tazemetostat molecule, its synthesis, and methods of treating specific cancers remain critical for Ipsen's ongoing market exclusivity.
Frequently Asked Questions
-
Does RE39198 cover the tazemetostat molecule itself?
No, RE39198 protects a pharmaceutical composition with a specific ratio of PEG and a substance that stimulates connective tissue growth or repair. It does not claim the tazemetostat molecule's structure or its primary oncological mechanism of action.
-
When did RE39198 expire, and what does this mean for generic Tazverik?
RE39198 expired on June 14, 2024. This expiration removes a potential barrier to generic entry for tazemetostat, but generic manufacturers must still ensure they do not infringe on other active patents held by Ipsen.
-
Can the claims of RE39198 be interpreted to cover the marketed formulation of Tazverik?
This depends on whether the marketed Tazverik formulation utilizes PEG within the weight ratios (approximately 2:1 to 50:1) and molecular weight specifications (approximately 1,000 to 10,000 daltons) claimed in the patent, and if its use falls within the scope of the patent's claims, notwithstanding the stated therapeutic purpose of connective tissue stimulation.
-
What is the significance of RE39198 being a "reissue" patent?
A reissue patent indicates that the original patent (U.S. Patent 5,484,966) was found to have an error, and a corrected patent was issued. This process can sometimes broaden or narrow claims from the original patent and is subject to specific legal standards.
-
Are there other patents protecting tazemetostat besides RE39198?
Yes, pharmaceutical companies typically file multiple patents to protect a drug. Ipsen likely holds patents covering the tazemetostat molecule, its synthesis, and specific methods of treating its approved indications (e.g., epithelioid sarcoma, follicular lymphoma).
Cited Sources
[1] United States Patent RE39198. (2006, July 25). Pharmaceutical composition. Espacenet. https://worldwide.espacenet.com/patent/search/family/0000081699063/publication/USRE39198E?q=RE39198
More… ↓
⤷ Start Trial
|
